- Home
- NUW vs GNFT Comparison
NUW vs GNFT Comparison
Compare NUW & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- GNFT
- Stock Information
- Founded
- NUW 2008
- GNFT 1999
- Country
- NUW United States
- GNFT France
- Employees
- NUW N/A
- GNFT N/A
- Industry
- NUW Investment Managers
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUW Finance
- GNFT Health Care
- Exchange
- NUW Nasdaq
- GNFT Nasdaq
- Market Cap
- NUW 245.0M
- GNFT 214.5M
- IPO Year
- NUW N/A
- GNFT 2019
- Fundamental
- Price
- NUW $13.66
- GNFT $3.73
- Analyst Decision
- NUW
- GNFT Strong Buy
- Analyst Count
- NUW 0
- GNFT 1
- Target Price
- NUW N/A
- GNFT $13.00
- AVG Volume (30 Days)
- NUW 45.3K
- GNFT 3.9K
- Earning Date
- NUW 01-01-0001
- GNFT 04-24-2025
- Dividend Yield
- NUW 3.66%
- GNFT N/A
- EPS Growth
- NUW N/A
- GNFT N/A
- EPS
- NUW N/A
- GNFT 0.03
- Revenue
- NUW N/A
- GNFT $73,187,701.00
- Revenue This Year
- NUW N/A
- GNFT $15.98
- Revenue Next Year
- NUW N/A
- GNFT N/A
- P/E Ratio
- NUW N/A
- GNFT $123.55
- Revenue Growth
- NUW N/A
- GNFT 105.01
- 52 Week Low
- NUW $12.45
- GNFT $2.55
- 52 Week High
- NUW $14.44
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- NUW 50.09
- GNFT 43.17
- Support Level
- NUW $13.54
- GNFT $3.55
- Resistance Level
- NUW $13.76
- GNFT $3.99
- Average True Range (ATR)
- NUW 0.08
- GNFT 0.16
- MACD
- NUW 0.00
- GNFT -0.06
- Stochastic Oscillator
- NUW 34.09
- GNFT 37.50
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.